Loading stock data…
Zentalis Pharmaceuticals, Inc. (ZNTL)
$4.03+0.04 (+1.00%)
Market ClosedLast close Sep 8
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zentalis Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.03 with a market capitalization of $382M. Wall Street consensus targets $6.89 (9 analysts), implying a +70.9% move over the next 12 months. The stock is currently 42% below its 52-week high of $6.95, remaining 23.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +70.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$37.85M↓ | -$37.39M↓ | -$33.73M↑ | -$36.06M↑ | -$37.83M |
| Net Income | -$35.35M↓ | -$35.22M↓ | -$26.69M↑ | -$26.87M↑ | -$48.28M |
Peer Comparison
JNJUNHPFE
Fundamentals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 cl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$381.53M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-97.15%
Volume
Today's trading volume
518,743
Recent News
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is one of the must-buy small cap stocks to buy. On April 10, Jefferies raised its price target on Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) from $2.50 to $6.00 and left the Hold rating unchanged. This decision came after Zentalis said it had selected the optimal dose of its lead cancer drug azenosertib […]
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone
Zentalis Pharmaceuticals (ZNTL) has drawn fresh attention after selecting a 400 mg once-daily, 5-days-on, 2-days-off dose of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer, based on interim DENALI Part 2a data. See our latest analysis for Zentalis Pharmaceuticals. The recent azenosertib dose selection and other trial updates have coincided with sharp share price momentum, with a 7 day share price return of 151.33% and a year to date share price return of 382.48%, even...
Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon
Zentalis Pharmaceuticals (NASDAQ:ZNTL) executives outlined a strategy centered on advancing its WEE1 inhibitor azenosertib toward potential approval in platinum-resistant ovarian cancer (PROC), emphasizing a targeted approach in patients with high cyclin E1 protein expression. Speaking at a Guggenhe